Related Experiment Video
Updated: Jun 5, 2026
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Neuropathic Gaucher disease.
1Departments of Neurology and Pediatrics, New York University School of Medicine, New York, USA. gregory.pastores@med.nyu.edu
Wiener Medizinische Wochenschrift (1946)
|January 12, 2011
Summary
Gaucher disease (GD) variants are classified by central nervous system (CNS) involvement. Recent findings show type 1 GD patients risk neurological issues, highlighting the need for better CNS therapies.
Area of Science:
- Neurology
- Genetics
- Metabolic Disorders
Background:
- Gaucher disease (GD) conventionally classified into types based on central nervous system (CNS) involvement.
- Type 1 GD was considered non-neuropathic, but emerging evidence indicates peripheral neuropathy and parkinsonian features.
- Neurologic manifestations in GD are challenging to treat with current therapies.
Purpose of the Study:
- To underscore the need for enhanced understanding of Gaucher disease's neurologic features.
- To explore the pathophysiologic basis of neurologic involvement in GD.
- To guide the development of novel therapeutic strategies for GD's neurologic aspects.
Main Methods:
- Review of existing literature on Gaucher disease clinical variants and neurologic manifestations.
- Analysis of recent studies identifying neurologic risks in type 1 GD patients.
- Exploration of therapeutic advancements in managing systemic GD features.
Main Results:
- Conventional GD classification may not fully capture neurologic risks, particularly in type 1.
- Peripheral neuropathy and parkinsonism are increasingly recognized in type 1 GD.
- Enzyme replacement therapy has shown success in systemic GD but limited impact on CNS involvement.
Conclusions:
- A deeper comprehension of GD's neurologic underpinnings is crucial.
- Targeted therapies addressing the pathophysiologic basis of neurologic involvement are needed.
- Improved neurologic outcomes in Gaucher disease patients are a key therapeutic goal.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...